Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.65 |
| ▸ | CNR1 | P21554 | 4/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.61 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.61 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.61 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.60 |
| ▸ | IDO1 | P14902 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2774874 | 0.94 | CNR1 (0.64) | TAAR1CNR1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL2773493 | 0.90 | EPHX2 (0.70) | TAAR1CNR1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL16936556 | 0.89 | CNR1 (0.60) | TAAR1CNR1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL6708022 | 0.84 | L3MBTL1 (0.49) | TAAR1CNR1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL5574769 | 0.82 | LMNA (0.66) | TAAR1CNR1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL1008891 | 0.82 | KDM4E (0.70) | TAAR1CNR1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL8581580 | 0.82 | IDO1 (0.68) | TAAR1CNR1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL1570160 | 0.82 | CA12 (0.48) | TAAR1L3MBTL1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL1437502 | 0.82 | KDM4E (0.69) | CYP1A2CYP2D6CYP2C19MAPTPLAAT3 | |
| SCHEMBL5034532 | 0.82 | L3MBTL1 (0.50) | L3MBTL1PLAAT3PLAAT5PLAAT2PLAAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673337-A2 | ARYLALKYLCARBAMATE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2006-06-28 | — | — | EP | claimed |
| WO-2005033066-A2 | ARYLALKYLCARBAMATE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2005-04-14 | — | — | WO | claimed |
| EP-3240784-A2 | INHIBITORS OF AKT KINASE | BerGenBio ASA (NO) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016102672-A2 | PHARMACEUTICALLY ACTIVE COMPOUNDS | BERGENBIO AS (NO) | 2016-06-30 | — | — | WO | disclosed |
| WO-2014060575-A2 | PROCESS FOR THE ENANTIOSELECTIVE SYNTHESIS OF A TETRAHYDROBENZAZEPINE COMPOUND | MEDICHEM S.A. (ES) | 2014-04-24 | — | — | WO | disclosed |
| EP-1972616-A1 | Derivatives of arylalkylcarbamates, process for their preparation and therapeutic application thereof | Sanofi-Aventis (FR) | 2008-09-24 | — | — | EP | disclosed |
| EP-1673337-A2 | ARYLALKYLCARBAMATE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2006-06-28 | — | — | EP | disclosed |
| US-6967196-B1 | Sulfonamide compounds and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-22 | — | — | US | disclosed |
| WO-2005033066-A2 | ARYLALKYLCARBAMATE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2005-04-14 | — | — | WO | disclosed |
| US-20040181094-A1 | Transition metal oxo complexes as catalysts of synthetic processes involving alkyne reactants | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2004-09-16 | — | — | US | disclosed |
| EP-0086018-B1 | PREPARING CARBAMIC ACID ESTERS | ANIC S.p.A. (IT) | 1985-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040181094-A1 | Transition metal oxo complexes as catalysts of synthetic processes involving alkyne reactants | POLR1G, PYM1, APEX1 | TAAR1 2949/4885CNR1 1784/4885CYP1A2 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.